Volume 14, Issue 2 (2-2026)                   JoMMID 2026, 14(2): 124-129 | Back to browse issues page

Ethics code: microbial pathogenesis

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Thennarasu A, Murugan N, Arumugam Samynathan A. Fusarium solani Species Complex as an Opportunistic Pathogen: A Case Series among Individuals with Underlying Conditions in a Tertiary Care Center. JoMMID 2026; 14 (2) :124-129
URL: http://jommid.pasteur.ac.ir/article-1-748-en.html
Fusarium solani Species Complex as an Opportunistic Pathogen: A Case Series among Individuals with Underlying Conditions in a Tertiary Care Center
Abhinaya Thennarasu * , Nishana Murugan , Aruna Arumugam Samynathan
Department of Microbiology, Chengalpattu Medical College, Chengalpattu, Tamil Nadu, India
Abstract:   (1035 Views)
Introduction: Fungal infections are an emerging threat in immunocompromised individuals. Among the causative agents, members of the Fusarium solani species complex (FSSC) are notable opportunistic pathogens. FSSC infections are associated with significant morbidity and mortality, largely because of the organism's aggressive nature and broad intrinsic resistance to several antifungal agents, particularly fluconazole, itraconazole, and echinocandins. Case presentations: This report describes three distinct cases of FSSC infection or isolation with varied clinical manifestations. The first case involved a 67-year-old male farmer who developed fungal keratitis following ocular trauma; corneal scraping cultures yielded an FSSC isolate. The second case involved a 55-year-old patient with a history of chronic obstructive pulmonary disease (COPD) who presented with an acute exacerbation. A computed tomography (CT) scan of the chest revealed a small area of consolidation, and sputum culture yielded an FSSC isolate, although airway colonization could not be excluded. The third case involved a 57-year-old patient with a history of alcoholic liver disease who developed progressive respiratory failure requiring mechanical ventilation. There was no clinical response to broad-spectrum antibiotic therapy. Subsequent blood cultures yielded an FSSC isolate, establishing fungemia. Conclusion: These cases underscore the diverse clinical presentations of FSSC-associated disease, particularly in patients with varying degrees of immune impairment, and demonstrate that favorable outcomes may be achievable with timely recognition and appropriate antifungal therapy. Early clinical suspicion and prompt mycological confirmation are essential, especially when patients fail to respond to empirical antibacterial treatment.
 
Keywords: Fungal keratitis, Fungemia, Fusariosis, Fusarium solani, Immunocompromised host, Pulmonary fusariosis
Full-Text [PDF 479 kb]   (102 Downloads)    
Type of Study: Case Report | Subject: Microbial pathogenesis
Received: 2025/07/10 | Accepted: 2026/02/21 | Published: 2026/09/7
References
1. Sarawade SS, Kanabar HP, Jadhav SS. A case report of fungal keratitis due to Fusarium oxysporum after an injury by fingernails. Indian J Ophthalmol Case Rep. 2023; 3 (1): 63-4. [DOI:10.4103/ijo.IJO_771_22]
2. Nucci M, Barreiros G, Akiti T, Anaissie E, Nouër S. Invasive fusariosis in patients with hematologic diseases. J Fungi (Basel). 2021; 7 (10): 815. [DOI:10.3390/jof7100815] [PMID] [PMCID]
3. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007; 20 (4): 695-704. [DOI:10.1128/CMR.00014-07] [PMID] [PMCID]
4. Sudhaharan S, Pamidimukkala U, Singh KN, Chavali P. Clinical spectrum of fusariosis from a tertiary care center in India: a retrospective study. Iran J Microbiol. 2024; 16 (1): 145-50. [DOI:10.18502/ijm.v16i1.14884] [PMID] [PMCID]
5. Batista BG, Chaves MA, Reginatto P, Saraiva OJ, Fuentefria AM. Human fusariosis: an emerging infection that is difficult to treat. Rev Soc Bras Med Trop. 2020; 53: e20200013. [DOI:10.1590/0037-8682-0013-2020] [PMID] [PMCID]
6. Short DPG, O'Donnell K, Thrane U, Nielsen NF, Zhang N, Juba JH, et al. Phylogenetic relationships among members of the Fusarium solani species complex in human infections and the descriptions of F. keratoplasticum sp. nov. and F. petroliphilum stat. nov. Fungal Genet Biol. 2013; 53: 59-70. [DOI:10.1016/j.fgb.2013.01.004] [PMID]
7. Castano G. Fungal Keratitis. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Feb. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493192/
8. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020; 71 (6): 1367-76. [DOI:10.1093/cid/ciz1008] [PMID]
9. Wang T, Yan M, Tang D, Dong Y, Zhu L, Du Q, et al. Using Child-Pugh class to optimize voriconazole dosage regimens and improve safety in patients with liver cirrhosis: insights from a population pharmacokinetic model-based analysis. Pharmacotherapy. 2021; 41 (2): 172-83. [DOI:10.1002/phar.2474] [PMID]
10. Zhao Y, Hou J, Xiao Y, Wang F, Zhang B, Chen M, et al. Predictors of voriconazole trough concentrations in patients with Child-Pugh class C cirrhosis: a prospective study. Antibiotics (Basel). 2021; 10 (9): 1130. [DOI:10.3390/antibiotics10091130] [PMID] [PMCID]
11. Goussous N, Abdullah A, Milner SM. Fusarium solani infection following burn injury: a case report. World J Plast Surg. 2019; 8 (3): 406-9.
12. Khurana A, Kumar A, Chauhan L. Clinical profile and treatment outcomes of Fusarium keratitis. Indian J Ophthalmol. 2022; 70 (3): 852-9. [DOI:10.4103/ijo.IJO_999_21] [PMID] [PMCID]
13. Liang B, Ni T, Ni W, Zhang X, Ai Q. Acute lymphoblastic leukemia with Fusarium solani infection: a case report. Front Med (Lausanne). 2025; 12: 1561843. [DOI:10.3389/fmed.2025.1561843] [PMID] [PMCID]
14. Al-Hatmi AM, Meis JF, de Hoog GS. Fusarium: molecular diversity and intrinsic drug resistance. PLoS Pathog. 2016; 12 (4): e1005464. [DOI:10.1371/journal.ppat.1005464] [PMID] [PMCID]
15. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dato D, Gangneux JP, et al. Global guideline for the diagnosis and management of rare invasive fungal infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology, the American Society for Microbiology, and the International Society for Tropical Pediatrics. Lancet Infect Dis. 2023; 23 (12): e478-e90.
16. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2012; 54 (2): 205-11.
17. Kim JY, Kang CI, Lee JH, Lee WJ, Huh K, Cho SY, et al. Clinical features and outcomes of invasive fusariosis: a case series in a single center with literature review. Infect Chemother. 2023; 55 (2): 290-4. [DOI:10.3947/ic.2018.0717] [PMID] [PMCID]
18. Sandoval-Denis M, Gené J, Cabañes FJ, Sutton DA, Cano-Lira JF, Guarro J. In vitro antifungal susceptibility and molecular identification of clinical Fusarium isolates. J Clin Microbiol. 2016; 54 (5): 1286-93.
19. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. 4th ed. CLSI standard M38. Wayne, PA: Clinical and Laboratory Standards Institute; 2022.
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.